To determine the effects of laparoscopic radical prostatectomy (LRP), or robot-assisted radical prostatectomy (RARP) compared with open radical prostatectomy (ORP) in men with localized prostate cancer.
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Objective To determine the effects of laparoscopic radical prostatectomy (LRP), or robot-assisted radical prostatectomy (RARP) compared with open radical prostatectomy (ORP) in men with localized prostate cancer.
Materials and Methods
We performed a comprehensive search using multiple databases (CENTRAL, MEDLINE, EMBASE) and abstract proceedings, with no restrictions on the language of publication or publication status, up until 9 June 2017. We included all randomized or pseudo-randomized controlled trials that directly compared LRP and RARP with ORP. Two review authors independently examined full-text reports, identified relevant studies, assessed the eligibility of studies for inclusion, extracted data and assessed risk of bias. We performed statistical analyses using a random-effects model and assessed the quality of the evidence according to Grading of Recommendations Assessment, Development and Evaluation (GRADE). The primary outcomes were prostate cancer-specific survival, urinary quality of life and sexual quality of life. Secondary outcomes were biochemical recurrence-free survival, overall survival, overall surgical complications, serious postoperative surgical complications, postoperative pain, hospital stay and blood transfusions.
Results
We included two unique studies in a total of 446 randomized participants with clinically localized prostate cancer. All available outcome data were short-term (up to 3 months). We found no study that addressed the outcome of prostate cancer-specific survival. Based on one trial, RARP probably results in little to no difference in urinary quality of life (mean difference [MD] À1.30, 95% confidence interval [CI] À4.65 to 2.05; moderate quality of evidence) and sexual quality of life (MD 3.90, 95% CI: À1.84 to 9.64; moderate quality of evidence). No study addressed the outcomes of biochemical recurrence-free survival or overall survival. Based on one trial, RARP may result in little to no difference in overall surgical complications (risk ratio [RR] 0.41, 95% CI: 0.16À1.04; low quality of evidence) or serious postoperative complications (RR 0.16, 95% CI: 0.02-1.32; low quality of evidence). Based on two studies, LRP or RARP may result in a small, possibly unimportant improvement in postoperative pain at 1 day (MD À1.05, 95% CI: À1.42 to À0.68; low quality of evidence) and up to 1 week (MD À0.78, 95% CI: À1.40 to À0.17; low quality of evidence). Based on one study, RARP probably results in little to no difference in postoperative pain at 12 weeks (MD 0.01, 95% CI: À0.32 to 0.34; moderate quality of evidence). Based on one study, RARP probably reduces the length of hospital stay (MD À1.72, 95% CI: À2.19 to À1.25; moderate quality of evidence). Based on two studies, LRP or RARP may reduce the frequency of blood transfusions (RR 0.24, 95% CI: 0.12-0.46; low quality of evidence). Assuming a baseline risk for a blood transfusion to be 8.9%, LRP or RARP would result in 68 fewer blood transfusions per 1,000 men (95% CI: 78-48 fewer).
Introduction
Prostate cancer is a leading disease affecting men worldwide and accounting for 15% of cancers diagnosed in men. In 2012, prostate cancer accounted for 14% of the total new cancers diagnosed worldwide, and 6% of total cancer deaths in men [1, 2] . Men diagnosed with localized prostate cancer have a variety of management options available, including radical prostatectomy. Other types of management include external beam radiation therapy, brachytherapy (including both high-and low-dose), active surveillance and watchful waiting, as well as investigational treatments, including whole-gland ablation therapy and focal-gland ablation therapy [3] [4] [5] .
Radical prostatectomy is recommended as a front-line treatment for men diagnosed with localized prostate cancer and with a life expectancy >10 years [3] [4] [5] . The late 1990s saw the introduction of laparoscopic radical prostatectomy (LRP) with the aim of reducing postoperative morbidity and allowing faster recovery when compared with traditional open radical prostatectomy (ORP) [6] . Initially, surgeons adopting the LRP approach needed to overcome significant technical challenges and a significant learning curve [7] . The robot-assisted radical prostatectomy approach (RARP) was introduced in the 2000s and has since been widely adopted, with technical innovations (three-dimensional visualization, articulated instruments, tremor filtration) which addressed some of the technical limitations of LRP [8, 9] .
While large prospective randomized controlled trials (RCTs) have reported the possible benefit of radical prostatectomy in men with low-and intermediate-risk prostate cancer, the effectiveness of LRP and RARP compared with ORP with regard to functional or oncological outcomes remains unclear [10] [11] [12] [13] . The aim of the present review, therefore, was to assess the effects of LRP or RARP compared with ORP in men with localized prostate cancer. This is an abridged version of a Cochrane review published in the Cochrane Library titled 'Laparoscopic and roboticassisted vs open radical prostatectomy for the treatment of localised prostate cancer' [14] .
Materials and Methods

Search Strategy and Selection Criteria
This systematic review and meta-analysis was based on published protocol [15] . We performed a comprehensive search using multiple databases of the Cochrane Central Register of Controlled Trials (1987-2017, issue 6) in the Cochrane Library, MEDLINE Ovid (1946 to 9 June 2017) and EMBASE Ovid (1974 to June 2017). We searched the bibliographies of identified studies for additional studies, and contacted authors of identified studies for knowledge of any published or unpublished studies, including new studies, additional studies, or works in progress. We hand-searched relevant conference proceedings from 2015 to 2017 for unpublished studies from annual meetings of the AUA and the European Association of Urology. Searches were initially performed on 13 December 2016, followed by an updated search on 9 June 2017. Two review authors (D.I. and C.A.) independently screened all potentially relevant records and classified studies in accordance with the criteria for each provided in the Cochrane Handbook for Systematic Reviews of Interventions [16] .
We reviewed RCTs, including pseudo-RCTs.
Types of Participants
We included studies recruiting men, aged ≥18 years, of any ethnicity, diagnosed with clinically localized prostate cancer. Men with a diagnosis of prostate cancer, who had been treated previously for prostate cancer with any intervention (e.g. surgery, brachytherapy, complementary medicines) were not eligible for inclusion.
Types of Intervention
The experimental intervention was LRP or RARP. The control intervention was ORP.
Types of Outcomes Measured
The primary outcomes of the review were prostate cancerspecific survival, urinary quality of life and sexual quality of [17] . Secondary outcomes were biochemical recurrence-free survival (defined as a PSA value 0.2 ng/mL after radical prostatectomy and confirmed by at least two consecutive measurements), overall survival, overall surgical complications, serious postoperative complications (such as postoperative haemorrhage requiring admission or intervention, or life-threatening complications), postoperative pain (assessed with validated questionnaires such as visual analogue scale score), hospital stay (measured as days from admission to discharge) and blood transfusions (measured as frequencies after surgery) [4] . We include a 'Summary of findings' table reporting the prostate cancer-specific survival, urinary quality of life, sexual quality of life, biochemical recurrence-free survival, overall survival and overall postoperative complications according to priority.
Data Collection and Data Extraction
Two review authors (D.I. and C.A.) independently assessed all studies using a data extraction form and followed the domain-based risk of bias evaluation as described in the Cochrane Handbook for Systematic Reviews of Interventions [16] .
We planned to extract hazard ratios (with 95% CIs for timeto-event outcomes. We attempted to obtain numbers of events and totals for population for dichotomous outcomes and means with standard deviations or data necessary to calculate this information for continuous outcomes. We summarized data using a random-effects model. We interpreted random-effects meta-analyses with due consideration of the whole distribution of effects.
We planned to assess heterogeneity statistically with the I 2 statistic. I 2 values of 25%, 50% and 75% were considered to indicate low, moderate and high heterogeneity, respectively, and values >50% were considered to indicate substantial heterogeneity [18] . Tests for funnel plot asymmetry are generally only performed when at least 10 studies are included in the meta-analysis. As our analysis included only two studies, tests for asymmetry would have been ineffective as they would have been unable to differentiate chance from asymmetry. We used REVIEW MANAGER 5 software (Cochrane Collaboration, Copenhagen, Denmark) to perform the statistical analyses.
We planned to conduct the following subgroup analyses: LRP vs RARP and T2 vs T3 disease (pathological tumour stage). We planned to perform sensitivity analyses in order to explore the influence of the following factor: restricting the analysis by taking into account risk of bias by excluding studies at 'high risk' or 'unclear risk'.
Summary of Findings Table
We presented the overall quality of the evidence for each outcome according to Grading of Recommendations Assessment, Development and Evaluation (GRADE), which takes into account five criteria not only related to internal validity (study limitations, inconsistency, imprecision, publication bias) but also to external validity such as directness of results [19] .
Results
Search Results
A search of all electronic databases returned 85 citations with no further records identified through other sources. After removal of duplicates, we found 49 citations eligible for screening against the inclusion criteria for this review. We excluded a total of 46 records based on reading the title and abstract. We screened three full-text articles, of which one was excluded [20] . We assessed two studies to be eligible for inclusion in this review [21, 22] . The flow of literature through the assessment process is shown in the flow chart in Fig. 1 .
Included Studies
This review included 446 randomized participants in total, of whom a total of 428 subsequently completed the study in the intervention and control groups. Table 1 [21, 22] shows the baseline characteristics of the included studies. Guazzoni et al. [21] compared LRP with ORP. LRP was performed via the transperitoneal route according to the Montsouris technique [23] , and ORP was performed using the anatomical technique described by Walsh [24] . Single surgeons performed all procedures. Yaxley et al. [22] compared RARP with ORP. Each surgical procedure was performed by the same surgeon. Pelvic lymph node dissection was performed in participants with a serum PSA >10 ng/mL, or a Gleason score >7 in both studies. Both studies used limited and standardized templates, respectively. Nerve-sparing procedures were undertaken based on preoperative variables, including clinical staging in both included studies. Pain control was undertaken based on analgesic protocol in one included study, but epidural or spinal anaesthesia was not used routinely in the other. Study outcomes were reported at up to 12 weeks postoperatively. While Guazzoni et al. [21] did not report either funding sources or conflicts of interests, Yaxley et al. [22] were supported by Cancer Council Queensland, without any competing interests.
Effect of the Intervention
Primary Outcomes
Neither of the two trials reported prostate cancer-specific survival outcome.
Yaxley et al. [22] reported data on urinary quality of life for 248 participants (RARP, n = 129; ORP, n = 119). RARP probably results in little to no difference in urinary quality of life (mean difference [MD] À1.30, 95% CI: À4.65 to 2.05).
We rated the quality of the evidence as moderate according to GRADE, downgrading for study limitations.
Yaxley et al. [22] reported data on sexual quality of life for 248 participants (RARP, n = 129; ORP, n = 119). RARP probably results in little to no difference in sexual quality of life (MD 3.90, 95% CI: À1.84 to 9.64). We rated the quality of the evidence as moderate according to GRADE, downgrading for study limitations.
Secondary Outcomes
Neither of the two trials included in the present review reported data on the secondary outcomes of biochemical recurrence-free survival and overall survival.
Yaxley et al. [22] reported data on overall surgical complications for 308 participants (RARP, n = 157; ORP, n = 151). RARP probably results in little to no difference in postoperative surgical complications (risk ratio [RR] 0.41, 95% CI: 0.16-1.04). We rated the quality of the evidence as low according to GRADE, downgrading for study limitations and imprecision.
Yaxley et al. [22] reported data on serious postoperative complications for 308 participants (RARP, n = 157; ORP, n = 151). RARP probably results in little to no difference in serious surgical complications (RR 0.16, 95% CI: 0.02-1.32).
We rated the quality of the evidence as low according to GRADE, downgrading for study limitations and imprecision.
We included two studies with 428 participants (LRP or RARP 217, ORP 211) and 370 participants (LRP or RARP 190, ORP 180) for postoperative follow-up at 1 day and up to 1 week [21, 22] . LRP or RARP may result in a small effect that may not be an important improvement in postoperative pain (at 1 day: MD À1.05, 95% CI: À1.42 to À0.68; up to 1 week: MD À0.78, 95% CI: À1.40 to À0.17).
We rated the quality of the evidence as low for both, according to GRADE, downgrading for study limitations and imprecision. We included only one study with 250 participants (RARP, n = 130; ORP, n = 120) with postoperative 12-week follow-up [22] . RARP probably We rated the quality of the evidence as moderate according to GRADE, downgrading for study limitations.
Yaxley et al. [22] reported data on length of hospital stay for 308 participants (RARP, n = 157; ORP, n = 151). RARP probably reduces the length of hospital stay (MD À1.72, 95% CI: À2.19 to À1.25). We rated the quality of the evidence as moderate according to GRADE, downgrading for study limitations.
Both the included studies reported data on blood transfusions for 428 participants (LRP or RARP, n = 217; ORP, n = 211). LRP or RARP may reduce the frequency of blood transfusions postoperatively (RR 0.24, 95% CI: 0.12-0.46). Assuming a baseline risk of blood transfusion to be 8.9% [25] , LRP or RARP would result in 68 fewer blood transfusions per 1,000 men (95% CI: 78 fewer to 48 fewer).
We rated the quality of the evidence as low according to GRADE, downgrading for study limitations and indirectness. We downgraded for indirectness because all participants in the one study banked two units of autologous blood, which may have increased transfusion requirements [21] .
Subgroup Analysis
We were not able to perform a subgroup analysis because there were no relevant data. 
Sensitivity Analysis
We were not able to perform a sensitivity analysis because of a paucity of included studies. Figure 2 summarizes the risk of bias assessment.
Risk of Bias
Allocation: Selection Bias
Both studies reported an adequate method of random sequence generation and we rated them at low risk of bias in this respect. With regard to allocation concealment, we rated both included studies as having unclear risk of bias because of a lack of information.
Blinding of Participants and Personnel: Performance Bias
We judged both included studies as at high risk of performance bias.
Blinding of Outcome Assessor: Detection Bias
We rated one study as low risk of bias [22] , but the other as unclear risk of bias [21] with regard to susceptible/subjective outcomes (prostate cancer-specific survival, urinary quality of life, sexual quality of life, biochemical recurrence-free survival, overall surgical complications, serious postoperative complications and postoperative pain).
We judged both included studies to have a low risk of bias with regard to non-susceptible/objective outcomes (overall survival, hospital stay and blood transfusions).
Incomplete Outcome Data: Attrition Bias
With regard to oncological outcomes (prostate cancer-specific survival, biochemical recurrence-free survival, overall survival), we rated one study as having a low risk of bias [22] , but the other as having unclear risk of bias [21] .
We rated one study as high risk of bias [22] , but the other as unclear risk of bias [21] with regard to quality-of-life outcomes (urinary and sexual quality of life).
With regard to overall surgical complications, serious postoperative complications, hospital stay and blood transfusions, we judged both included studies as having a low risk of bias.
We rated one study as low risk of bias [21] , but the other as high risk of bias [22] for postoperative pain outcomes.
Selective Reporting: Reporting Bias
We rated one study, which had a published protocol, as at low risk of reporting bias [22] , but the other as unclear risk of reporting bias [21] .
Other Potential Sources of Bias
We rated one study as low risk of other potential bias [22] , but the other as unclear risk of bias because of an imbalance in the number of nerve-sparing procedures between the interventions, which may have affected the prognosis [21] .
Summary of Findings
The findings of the present review are provided in a summary of findings table in accordance with GRADE methodology (Table 2) .
Discussion
A systematic search of the literature identified no published systematic reviews of RCTs, clinical practice guidelines reporting findings, or recommendations, with respect to the use of ORP vs LRP in the treatment of localized prostate cancer. Several systematic reviews of observational studies have been completed, and generally support the findings reported in the present systematic review [7, [26] [27] [28] [29] [30] . Previous systematic review evidence from observational studies has demonstrated lower rates of blood loss, blood transfusion, postoperative complications, pain and length of hospital stay for patients undergoing LRP/RARP [27, 28, 30, 31] , while urinary and sexual quality of life have been reported in observational studies to be significantly better in men receiving RARP compared with ORP [29] . Evidence from previous systematic reviews of non-RCTs, however, has uniformly concluded that the quality of the evidence base on observational studies is low [16, 32] . None of these studies used GRADE to assess the quality of evidence. Findings from our systematic review support previous findings that have reported lower rates of blood transfusion, postoperative pain, and length of hospital stay in LRP/RARP groups [27, 29, 31] .
The present review has some limitations with regard to applicability of evidence. It is based on only two RCTs with relatively small sample sizes and event rates conducted at tertiary care centres with expert surgeons [21, 22] . This narrow evidence base stands in marked contrast to the widespread use of RARP in many countries, in particular in the USA [33] . All outcome data, including quality-of-life data, were short-term. Given that prostate cancer survivorship, which includes dealing with the potential adverse events of radical surgery, such as urinary incontinence and erectile dysfunction, commonly extends over decades, the information provided appears insufficient to guide clinical practice. Estimates for control event rates for surgical complications come from Gandaglia et al. [25] .
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Longer-term, well-controlled studies are needed. One of the central challenges of assessing surgical innovation lies in the need to account for ongoing evolution of the procedure or device, or both, being used, as well as accounting for the surgical learning curve [34, 35] . It is well recognized that surgical outcomes are dependent on surgeons' and centres' volume and experience. The present review is unable to account for these differences, which may be more important factors than the surgical approach. While RARP (and less so today, LRP) has tremendous appeal to surgeons, because of, among other things, magnification of the operative field and three-dimensional imaging, device acquisition and maintenance/service are costly [8, 9, 26] . However, an assessment of the cost-effectiveness of LRP/RARP was outside the scope of the present review. Given that the indication for radical surgery is motivated by men's concern about prostate cancer-related morbidity and mortality, a major limitation of the evidence drawn from this review is the lack of high-quality evidence to inform the comparison of any oncological outcomes, resulting in major uncertainty. An understanding of these outcomes, therefore, has to come from observational studies that were outside the scope of this review and are likely to only yield low-quality evidence [32] .
Whilst there is an urgent need to raise methodological standards for clinical research on new urological procedures and devices, the reality of creating future RCTs may be restricted by the challenges of conducting controlled trials of surgical interventions [36] . A better understanding of the impact of LRP/RARP on oncological outcomes is needed.
